BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
| Author: | Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T. Lemke, Nicolas D. WerbeckGND, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer Roth, Douglas Daniels, Virendar K. Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R. Golub |
|---|---|
| DOI: | https://doi.org/10.1038/s43018-024-00814-0 |
| ISSN: | 2662-1347 |
| Parent Title (English): | Nature Cancer |
| Document Type: | Article (peer-reviewed) |
| Language: | English |
| Year of Completion: | 2024 |
| Release Date: | 2024/11/28 |
| Volume: | 5.2024 |
| Issue: | 10 |
| First Page: | 1479 |
| Last Page: | 1493 |
| Open-Access-Status: | Open Access |
| Gold | |
| Licence (German): |  Creative Commons - CC BY - Namensnennung 4.0 International |